Graffinity and Mutabilis announce second research collaboration
Drug Discovery Collaboration to Focus on Infectious Disease Targets
Graffinity announced that it has entered into its second research collaboration with Mutabilis, a French drug discovery company, to discover novel therapeutics for infectious diseases. Mutabilis and Graffinity have already collaborated on an antiinfective drug target in 2003, and Mutabilis has decided to return to Graffinity for the screening and identification of small molecule compounds against a number of key targets.
Under the terms of the agreement Mutabilis will provide Graffinity with target proteins identified by Mutabilis. Graffinity will apply its proprietary RAISE® (Rapid Affinity Instructed Structure Evolution) Technology and drug-fragment chemical microarrays to identify and evolve small molecule hit structures with a focus on compounds with novel modes of action. Graffinity will receive a technology access fee and a milestone payment upon conclusion of the collaboration.
Other news from the department business & finance
